Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email


Check back regularly for news, coverage, and announcements about MAVA.


Epidarex Capital Invests in Cancer Drug Developer Confluence Life Sciences Inc.

Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory disease.    

Confluence’s innovative KINect Technology Platform enables the identification and development of new protein kinase drugs in a fraction of the time of other approaches.  Confluence’s team of world-class drug developers has created a pipeline of drug candidates which focus on creating kinase inhibitors targeting hard-to-treat cancers.  Confluence’s lead program targets the kinase TAK1, which is important in cancer cell transformation, metastasis, tumor growth and drug resistance, especially in pancreatic and other cancers such as breast and colon. 

Pancreatic cancer killed an estimated 38,460 people in the US last year.   It is the fourth leading cause of cancer death in the US, with an average survival time following diagnosis of 4-6 months, among the lowest for all types of cancer. Confluence’s goal is to develop an orally active, small molecule drug to significantly improve survival in pancreatic and other cancers, and to potentially treat chronic inflammatory disease.

Epidarex Capital’s financing will support Confluence’s identification and development of its lead drug candidates.  Epidarex Managing Partner Kyp Sirinakis will join the Board of Directors at Confluence.  Epidarex joins existing investors Mercury Fund, BioGenerator and Missouri Technology Corporation. 

Confluence is Epidarex Capital’s second investment from its US fund.  Epidarex focuses on providing early-stage risk capital to top researchers and entrepreneurs in the US and UK who are developing highly innovative solutions for the global healthcare market.

Learn More